Raymond James upgraded Universal Health (UHS) to Outperform from Market Perform with a $270 price target The company’s Q3 results were above guidance and consensus forecasts, showing improved execution, the analyst tells investors in a research note. The firm says Universal Health also faces easy comparisons for 2026 while the shares trade at an attractive valuation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health price target raised to $231 from $206 at RBC Capital
- Universal Health price target raised to $302 from $280 at UBS
- Universal Health price target raised to $233 from $200 at Morgan Stanley
- Universal Health: Balanced Outlook Amid MSPP Gains and Medicaid Challenges
- Universal Health price target raised to $253 from $227 at Guggenheim